Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives

Valerio De Stefano; Elena Rossi

doi:10.1160/TH13-01-0011

Thrombosis and Haemostasis, Inhaltsverzeichnis

Thromb Haemost 2013; 110(04): 697-705
DOI: 10.1160/TH13-01-0011

Review Article

Schattauer GmbH

Testing for inherited thrombophilia and consequences for antithrombotic prophylaxis in patients with venous thromboembolism and their relatives

A review of the Guidelines from Scientific Societies and Working Groups

Valerio De Stefano

¹Institute of Hematology, Catholic University, Rome, Italy

,

Elena Rossi

¹Institute of Hematology, Catholic University, Rome, Italy

› Institutsangaben

Abstract

Summary

The clinical penetrance of venous thromboembolism (VTE) susceptibility genes is variable, being lower in heterozygous carriers of factor V Leiden and prothrombin 20210A (mild thrombophilia), and higher in the rare carriers of deficiencies of antithrombin, protein C or S, and those with multiple or homozygous abnormalities (high-risk thrombophilia). The absolute risk of VTE is low, and the utility of laboratory investigation for inherited thrombophilia in patients with VTE and their asymptomatic relatives has been largely debated, leading to the production of several Guidelines from Scientific Societies and Working Groups. The risk for VTE largely depends on the family history of VTE. Therefore, indiscriminate search for carriers is of no utility, and targeted screening is potentially more fruitful. In patients with VTE inherited thrombophilia is not scored as a determinant of recurrence, playing a minor role in the decision of prolonging anticoagulation; indeed, a few guidelines consider testing worthwhile to identify carriers of high-risk thrombophilia, particularly those with a family history of VTE. The identification of the asymptomatic carrier relatives of the probands with VTE and thrombophilia could reduce cases of provoked VTE, offering them primary antithrombotic prophylaxis during risk situations. In most guidelines, this is considered justified only for relatives of probands with a deficiency of natural anticoagulants or multiple abnormalities. Counselling the asymptomatic female relatives of individuals with VTE and/or thrombophilia before pregnancy or the prescription of hormonal treatments should be administered with consideration of the risk driven by the type of thrombophilia and the family history of VTE.

Keywords

Inherited thrombophilia - guidelines - venous thromboembolism - laboratory investigation - familial investigation

Volltext

Referenzen

References
1 De Stefano V, Rossi E, Paciaroni K. et al. Screening for inherited thrombophilia: indications and therapeutic implications. Haematologica 2002; 87: 1095-1108.
2 De Stefano V. Inherited thrombophilia and life-time risk of venous thromboembolism: is the burden reducible?. J Thromb Haemost 2004; 2: 1522-1525.
3 Vossen CY, Conard J, Fontcuberta J. et al. Familial thrombophilia and life-time risk of venous thrombosis. J Thromb Haemost 2004; 2: 1526-1532.
4 Vossen CY, Conard J, Fontcuberta J. et al. Risk of a first venous thrombotic event in carriers of a familial thrombophilic defect. The European Prospective Cohort on Thrombophilia (EPCOT). J Thromb Haemost 2005; 3: 459-464.
5 Middeldorp S, van Hylckama Vlieg A. Does thrombophilia testing help in the clinical management of patients?. Br J Haematol 2008; 143: 321-335.
6 Makris M. Thrombophilia: grading the risk. Blood 2009; 113: 5038-5039.
7 Lijfering WM, Brouwer JL, Veeger NJ. et al. Selective testing for thrombophilia in patients with first venous thrombosis: results from a retrospective family cohort study on absolute thrombotic risk for currently known thrombophilic defects in 2479 relatives. Blood 2009; 113: 5314-5322.
8 Carraro P. European Communities Confederation of Clinical Chemistry and Laboratory Medicine, Working Group on Guidelines for Investigation of Disease. Guidelines for the laboratory investigation of inherited thrombophilias. Recommendations for the first level clinical laboratories. Clin Chem Lab Med 2003; 41: 382-391.
9 European Genetics Foundation; Cardiovascular Disease Educational and Research Trust; International Union of Angiology; Mediterranean League on Thromboembolism. Nicolaides AN, Breddin HK, Carpenter P. et al. Thrombophilia and venous thromboembolism. International consensus statement. Guidelines according to scientific evidence. Int Angiol 2005; 24: 1-26.
10 Lussana F, Dentali F, Abbate R. et al. Italian Society for Haemostasis and Thrombosis. Screening for thrombophilia and antithrombotic prophylaxis in pregnancy: Guidelines of the Italian Society for Haemostasis and Thrombosis (SISET). Thromb Res 2009; 124: e19-e25.
11 Pernod G, Biron-Andreani C, Morange PE. et al. French group on haemostasis and thrombosis; French Society of vascular medicine. Recommendations on testing for thrombophilia in venous thromboembolic disease: a French consensus guideline. J Mal Vasc 2009; 34: 156-203.
12 Baglin T, Gray E, Greaves M. et al. British Committee for Standards in Haematology. Clinical guidelines for testing for heritable thrombophilia. Br J Haematol 2010; 149: 209-220.
13 Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: routine testing for Factor Leiden (R506Q) and prothrombin (20210G>A) mutations in adults with a history of idiopathic venous thromboembolism and their adult family members. Genet Med 2011; 13: 67-76.
14 NICE. Venous thromboembolic diseases: the management of venous thromboembolic diseases and the role of thrombophilia testing. Clinical guideline 144. London: National Institute for Health and Clinical Excellence; 2012. .
15 Kearon C, Akl EA, Comerota AJ. et al. American College of Chest Physicians. Antithrombotic therapy for VTE disease: Antithrombotic therapy and prevention of thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e419S-e94S.
16 de Moerloose P, Boehlen F. Inherited thrombophilia in arterial disease: a selective review. Semin Hematol 2007; 44: 106-113.
17 Royal College of Obstetricians and Gynaecologists. The investigation and treatment of couples with recurrent first-trimester and second-trimester miscarriage. Green-top Guideline No. 17, 2011; Available at www.rcog.org.uk
18 Dallapiccola B, Agolini E, Morena A. et al. Censimento 2007 delle attivitàdelle strutture di genetica medica in Italia. Analysis 2009; 4/5: 207-232.
19 Suthers G. Report of the Australian Genetic Testing Survey 2006. Royal College of Pathologists of Australasia, 2009. Available at www.rcpa.edu.au/static/File/Assetlibrary/publicdocuments/MediaReleases/AustralianGeneSurvey2006.pdf
20 Coppens M, van Mourik JA, Eckmann CM. et al. Current practise of testing for inherited thrombophilia. J Thromb Haemost 2007; 5: 1979-1981.
21 Laberge AM, Psaty BM, Hindorff LA. et al. Use of Factor V Leiden genetic testing in practice and impact on management. Genet Med 2009; 11: 750-756.
22 Gartner V, Weber M, Eichinger S. The emotional impact of genetic testing and aspects of counseling prior to prescription of OC. Contraception 2008; 78: 392-398.
23 Seligsohn U, Lubetsky A. Genetic susceptibility to venous thrombosis. N Engl J Med 2001; 344: 1222-1231.
24 Ridker PM, Glynn RJ, Miletich JP. et al. Age-specific incidence rates of venous thromboembolism among heterozygous carriers of factor V Leiden mutation. Ann Intern Med 1997; 126: 528-531.
25 De Stefano V, Rossi E, Paciaroni K. et al. Different circumstances of the first venous thromboembolism among younger or older heterozygous carriers of the G20210A polymorphism in the prothrombin gene. Haematologica 2003; 88: 61-66.
26 Roldan V, Lecumberri R, Muñoz-Torrero JF. et al. RIETE Investigators. Thrombophilia testing in patients with venous thromboembolism. Findings from the RIETE registry. Thromb Res 2009; 124: 174-177.
27 Prandoni P, Noventa F, Ghirarduzzi A. et al. The risk of recurrent venous thromboembolism after discontinuing anticoagulation in patients with acute proximal deep vein thrombosis or pulmonary embolism. A prospective cohort study in 1,626 patients. Haematologica 2007; 92: 199-205.
28 Hansson PO, Sorbo J, Eriksson H. Recurrent venous thromboembolism after deep vein thrombosis: incidence and risk factors. Arch Intern Med 2000; 160: 769-774.
29 Baglin T, Luddington R, Brown K. et al. Incidence of recurrent venous thromboembolism in relation to clinical and thrombophilic risk factors: prospective cohort study. Lancet 2003; 362: 523-526.
30 Christiansen SC, Cannegieter SC, Koster T. et al. Thrombophilia, clinical factors, and recurrent venous thrombotic events. J Am Med Assoc 2005; 293: 2352-2361.
31 Simioni P. Risk of recurrent venous thromboembolism and thrombophilia: does discrepancy make complexity or vice versa?. J Thromb Haemost 2003; 1: 16-18.
32 Baglin T. Using the laboratory to predict recurrent venous thrombosis. Int J Lab Hematol 2011; 33: 333-342.
33 Tosetto A, Iorio A, Marcucci M. et al. Predicting disease recurrence in patients with previous unprovoked venous thromboembolism: a proposed prediction score (DASH). J Thromb Haemost 2012; 10: 1019-1025.
34 Ho WK, Hankey GJ, Quinlan DJ. et al. Risk of recurrent venous thromboembolism in patients with common thrombophilia: a systematic review. Arch Intern Med 2006; 166: 729-736.
35 Marchiori A, Mosena L, Prins MH. et al. The risk of recurrent venous thromboembolism among heterozygous carriers of factor V Leiden or prothrombin G20210A mutation. A systematic review of prospective studies. Haematologica 2007; 92: 1107-1114.
36 Segal JB, Brotman DJ, Necochea AJ. et al. Predictive value of factor V Leiden and prothrombin G20210A in adults with venous thromboembolism and in family members of those with a mutation: a systematic review. J Am Med Assoc 2009; 301: 2472-2485.
37 Coppens M, Reijnders JH, Middeldorp S. et al. Testing for inherited thrombophilia does not reduce recurrence of venous thrombosis. J Thromb Haemost 2008; 6: 1474-1477.
38 Cohn DM, Vansenne F, de Borgie CA. et al. Thrombophilia testing for prevention of recurrent venous thromboembolism. Cochrane Database Syst Rev 2012; 12: CD007069.
39 Palareti G, Legnani C, Cosmi B. et al. Predictive value of D-dimer test for recurrent venous thromboembolism after anticoagulation withdrawal in subjects with a previous idiopathic event and in carriers of congenital thrombophilia. Circulation 2003; 108: 313-318.
40 Allaart CF, Poort SR, Rosendaal FR. et al. Increased risk of venous thrombosis in carriers of hereditary protein C deficiency defect. Lancet 1993; 341: 134-138.
41 Engesser L, Broekmans AW, Briët E. et al. Hereditary protein S deficiency: clinical manifestations. Ann Intern Med 1987; 106: 677-682.
42 Zöller B, Berntsdotter A, García de Frutos P. et al. Resistance to activated protein C as an additional genetic risk factor in hereditary deficiency of protein S. Blood 1995; 85: 3518-3523.
43 De Stefano V, Simioni P, Rossi E. et al. The risk of recurrent venous thromboembolism in patients with inherited deficiency of natural anticoagulants antithrombin, protein C, and protein S. Haematologica 2006; 91: 695-698.
44 Vossen CY, Walker ID, Svensson P. et al. Recurrence rate after a first venous thrombosis in patients with familial thrombophilia. Arterioscler Thromb Vasc Biol 2005; 25: 1992-1997.
45 Brouwer JL, Lijfering WM, Ten Kate MK. et al. High long-term absolute risk of recurrent venous thromboembolism in patients with hereditary deficiencies of protein S, protein C or antithrombin. Thromb Haemost 2009; 101: 93-99.
46 De Stefano V, Martinelli I, Mannucci PM. et al. The risk of recurrent deep venous thrombosis among heterozygous carriers of both factor V Leiden and the G20210A prothrombin mutation. N Engl J Med 1999; 341: 801-806.
47 Margaglione M, D’Andrea G, Colaizzo D. et al. Coexistence of factor V Leiden and Factor II A20210 mutations and recurrent venous thromboembolism. Thromb Haemost 1999; 82: 1583-1587.
48 Nowak-Gottl U, Junker R, Kreuz W. et al. Childhood Thrombophilia Study Group. Risk of recurrent venous thrombosis in children with combined prothrombotic risk factors. Blood 2001; 97: 858-862.
49 Meinardi JR, Middeldorp S, de Kam PJ. et al. The incidence of recurrent venous thromboembolism in carriers of factor V Leiden is related to concomitant thrombophilic disorders. Br J Haematol 2002; 116: 625-631.
50 The Procare Group. Is recurrent venous thromboembolism more frequent in homozygous patients for the factor V Leiden mutation than in heterozygous patients?. Blood Coagul Fibrinolysis 2003; 14: 523-529.
51 Martinelli I, De Stefano V. Rare thromboses of cerebral, splanchnic and upper-extremity veins. A narrative review. Thromb Haemost 2010; 103: 1136-1144.
52 Einhäupl K, Stam J, Bousser MG. et al. European Federation of Neurological Societies. EFNS guideline on the treatment of cerebral venous and sinus thrombosis in adult patients. Eur J Neurol 2010; 17: 1229-1235.
53 Ageno W, Dentali F, Squizzato A. et al. Evidence and clinical judgment: treatment of cerebral vein thrombosis. Thromb Haemost 2010; 103: 1109-1115.
54 DeLeve LD, Valla DC, Garcia-Tsao G. American Association for the Study Liver Diseases. Vascular disorders of the liver. Hepatology 2009; 49: 1729-1764.
55 Tait C, Baglin T, Watson H. et al. British Committee for Standards in Haematology. Guidelines on the investigation and management of venous thrombosis at unusual sites. Br J Haematol 2012; 159: 28-38.
56 Decousus H, Moulin N, Quenet S. et al. Trombophilia and risk of venous thrombosis in patients with cancer. Thromb Res 2007; 120 (Suppl. 02) S51-S61.
57 Horowitz N, Brenner B. Thrombophilia and cancer. Pathophysiol Haemost Thromb 2008; 36: 131-136.
58 Dentali F, Gianni M, Agnelli G. et al. Association between inherited thrombophilic abnormalities and central venous catheter thrombosis in patients with cancer: a meta-analysis. J Thromb Haemost 2008; 6: 70-75.
59 Caruso V, Iacoviello L, Di Castelnuovo A. et al. Thrombotic complications in childhood acute lymphoblastic leukemia: a meta-analysis of 17 prospective studies comprising 1752 pediatric patients. Blood 2006; 108: 2216-2222.
60 Farge D, Debourdeau P, Beckers M. et al. International clinical practice guidelines for the treatment and prophylaxis of venous thromboembolism in patients with cancer. J Thromb Haemost 2013; 11: 56-70.
61 Harlev D, Zaidman I, Sarig G. et al. Prophylactic therapy with enoxaparin in children with acute lymphoblastic leukemia and inherited thrombophilia during L-asparaginase treatment. Thromb Res 2010; 126: 93-97.
62 Wu O, Robertson L, Twaddle S. et al. Thrombosis: Risk and Economic Assessment of Thrombophilia Screening (TREATS) Study. Screening for thrombophilia in high-risk situations: a meta-analysis and cost-effectiveness analysis. Br J Haematol 2005; 131: 80-90.
63 Vandenbroucke JP, van der Meer FJM, Helmerhorst FM. et al. Factor V Leiden: should we screen oral contraceptive users and pregnant women?. Br Med J 1996; 313: 1127-1130.
64 Clark P, Twaddle S, Walker ID. et al. Cost-effectiveness of screening for the factor V Leiden mutation in pregnant women. Lancet 2002; 359: 1919-1920.
65 Grody WW, Griffin JH, Taylor AK. et al. ACMG Factor V Leiden Working Group. American College of Medical Genetics consensus statement on factor V Leiden mutation testing. Genet Med 2001; 3: 139-148.
66 Recommendations of the European Society of Human Genetics. Provision of genetic services in Europe: current practices and issues. Eur J Hum Genet 2003; 11 (Suppl. 02) S2-S4.
67 Recommendations of the European Society of Human Genetics. Population genetic screening programmes: technical, social and ethical issues. Eur J Hum Genet 2003; 11 (Suppl. 02) S5-S7.
68 Green D. Genetic hypercoagulability: screening should be an informed choice. Blood 2001; 98: 20.
69 Mannucci PM. Genetic hypercoagulability: prevention suggests testing family members. Blood 2001; 98: 21-22.
70 Martinelli I. Pros and cons of thrombophilia testing: pros. J Thromb Haemost 2003; 1: 410-411.
71 Machin SJ. Pros and cons of thrombophilia testing: cons. J Thromb Haemost 2003; 1: 412-413.
72 Bank I, Scavenius MP, Büller HR. et al. Social aspects of genetic testing for factor V Leiden mutation in healthy individuals and their importance for daily practice. Thromb Res 2004; 113: 7-12.
73 Tosetto A, Frezzato M, Rodeghiero F. Prevalence and risk factors of non-fatal venous thromboembolism in the active population of the VITA Project. J Thromb Haemost 2003; 1: 1724-1729.
74 Noboa S, Le Gal G, Lacut K. et al. EDITH Collaborative Study Group. Family history as a risk factor for venous thromboembolism. Thromb Res 2008; 122: 624-629.
75 Bezemer ID, van der Meer FJ, Eikenboom JC. et al. The value of family history as a risk indicator for venous thrombosis. Arch Intern Med 2009; 169: 610-615.
76 Zöller B, Li X, Sundquist J. et al. Parental history and venous thromboembolism: a nationwide study of age-specific and sex-specific familial risks in Sweden. J Thromb Haemost 2011; 9: 64-70.
77 Sørensen HT, Riis AH, Diaz LJ. et al. Familial risk of venous thromboembolism: a nationwide cohort study. J Thromb Haemost 2011; 9: 320-324.
78 Zöller B, Ohlsson H, Sundquist J. et al. Familial risk of venous thromboembolism in first-, second- and third-degree relatives: a nationwide family study in Sweden. Thromb Haemost 2013; 109: 458-463.
79 Lensen RP, Bertina RM, de Ronde H. et al. Venous thrombotic risk in family members of unselected individuals with factor V Leiden. Thromb Haemost 2000; 83: 817-821.
80 Rossi E, Ciminello A, Za T. et al. In families with inherited thrombophilia the risk of venous thromboembolism is dependent on the clinical phenotype of the proband. Thromb Haemost 2011; 106: 646-654.
81 Duhl AJ, Paidas MJ, Ural SH. et al. Pregnancy and Thrombosis Working Group. Antithrombotic therapy and pregnancy: consensus report and recommendations for prevention and treatment of venous thromboembolism and adverse pregnancy outcomes. Am J Obstet Gynecol 2007; 197: 457 e1-21
82 Royal College of Obstetricians and Gynaecologists. Thrombosis and embolism during pregnancy and the puerperium. Reducing the risk. Green-top Guideline No. 37a, 2009. Available at www.rcog.org.uk
83 Scottish Intercollegiate Guidelines Network. Prevention and management of venous thromboembolism. A national clinical guideline. SIGN publication no. 122, 2010. Available at www.sign.ac.uk
84 Lockwood C, Wendel G. Committee on Practice Bulletins— Obstetrics. Practice bulletin no. 124: inherited thrombophilias in pregnancy. Obstet Gynecol 2011; 118: 730-740.
85 Bates SM, Greer IA, Middeldorp S. et al. American College of Chest Physicians. VTE, thrombophilia, antithrombotic therapy, and pregnancy: Antithrombotic Therapy and Prevention of Thrombosis, 9th ed: American College of Chest Physicians Evidence-Based Clinical Practice Guidelines. Chest 2012; 141 (Suppl. 02) e691S-e736S.
86 McLintock C, Brighton T, Chunilal S. et al. Councils of the Society of Obstetric Medicine of Australia and New Zealand; Australasian Society of Thrombosis and Haemostasis. Recommendations for the prevention of pregnancy-associated venous thromboembolism. Aust N Z J Obstet Gynaecol 2012; 52: 3-13.
87 Royal College of Obstetricians and Gynaecologists. Venous thromboembolism and hormonal contraception. Green-top Guideline No. 40, 2010. Available at www.rcog.org.uk
88 Royal College of Obstetricians and Gynaecologists. Venous thromboembolism and hormone replacement therapy. Green-top Guideline No. 11, 2011. Available at www.rcog.org.uk
89 Wilson BJ, Qureshi N, Santaguida P. et al. Systematic review: family history in risk assessment for common diseases. Ann Intern Med 2009; 151: 878-885.
90 Behera M, Kumar A, Soares HP. et al. Evidence-based medicine for rare diseases: implications for data interpretation and clinical trial design. Cancer Control 2007; 14: 160-166.